Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Fluvoxamine is a widely prescribed antidepressant belonging to the class of selective serotonin reuptake inhibitors (SSRIs). Its molecular formula is C13H17F2N3O2, and it carries the CAS registry number 58622-40-9. First synthesized in the late 1970s, this compound was developed to modulate neurotransmitter levels in the brain with high specificity for serotonin transporters. By inhibiting the reuptake of serotonin into presynaptic neurons, Fluvoxamine increases the concentration of this neurotransmitter in the synaptic cleft, thereby enhancing serotonergic transmission and alleviating symptoms associated with mood disorders.
The primary clinical indication for Fluvoxamine is the treatment of Obsessive-Compulsive Disorder (OCD) in both adults and children. It helps reduce the frequency and intensity of obsessions and compulsions, significantly improving daily functioning and quality of life. Beyond OCD, it is frequently utilized off-label or as an alternative therapy for major depressive disorder, panic disorder, and social anxiety disorder. Its mechanism involves blocking the serotonin transporter protein without significant affinity for other receptors, which generally results in a favorable side effect profile compared to older tricyclic antidepressants. However, common adverse effects may include nausea, drowsiness, insomnia, and sexual dysfunction.
Pharmacokinetically, Fluvoxamine undergoes extensive hepatic metabolism via cytochrome P450 enzymes, particularly CYP1A2 and CYP2C19. This metabolic pathway necessitates careful monitoring when co-administered with other drugs that inhibit or induce these enzymes, as interactions can lead to toxic plasma levels or therapeutic failure. The drug is available in immediate-release tablets and extended-release formulations, allowing for flexible dosing strategies tailored to individual patient needs. While not curative, long-term use often maintains remission in chronic conditions. Patients must be advised on the gradual onset of action, which typically requires several weeks to manifest full therapeutic benefits. Overall, Fluvoxamine remains a cornerstone medication in modern psychiatry for managing anxiety-related and depressive pathologies effectively.